282 related articles for article (PubMed ID: 24136072)
1. Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?
Rubboli A; Oldgren J; Marìn F; Lip G
Intern Emerg Med; 2013 Dec; 8(8):673-80. PubMed ID: 24136072
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
[TBL] [Abstract][Full Text] [Related]
3. Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
Spinthakis N; Farag M; Akhtar Z; Gorog DA
Curr Vasc Pharmacol; 2018; 16(5):427-436. PubMed ID: 29345587
[TBL] [Abstract][Full Text] [Related]
4. Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review.
Khalil P; Kabbach G
Curr Cardiol Rep; 2019 Jan; 21(1):5. PubMed ID: 30689068
[TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulants in acute coronary syndrome.
Ahrens I; Bode C
Semin Hematol; 2014 Apr; 51(2):147-51. PubMed ID: 24861799
[TBL] [Abstract][Full Text] [Related]
6. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
7. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.
Oldgren J; Wallentin L; Alexander JH; James S; Jönelid B; Steg G; Sundström J
Eur Heart J; 2013 Jun; 34(22):1670-80. PubMed ID: 23470494
[TBL] [Abstract][Full Text] [Related]
8. Novel oral anticoagulants in acute coronary syndrome.
Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
[TBL] [Abstract][Full Text] [Related]
9. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Parker WA; Storey RF
Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
[TBL] [Abstract][Full Text] [Related]
10. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
Rubboli A; Agewall S; Huber K; Lip GY
Int J Cardiol; 2015 Oct; 196():133-8. PubMed ID: 26093527
[TBL] [Abstract][Full Text] [Related]
11. Individualized antithrombotic therapy.
Lüscher TF; Steffel J
Hamostaseologie; 2016; 36(1):26-32. PubMed ID: 25597592
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Jiang M; You JHS
Clin Cardiol; 2017 Oct; 40(10):789-796. PubMed ID: 28683175
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention.
D'Ascenzo F; Taha S; Moretti C; Omedè P; Grossomarra W; Persson J; Lamberts M; Dewilde W; Rubboli A; Fernández S; Cerrato E; Meynet I; Ballocca F; Barbero U; Quadri G; Giordana F; Conrotto F; Capodanno D; DiNicolantonio J; Bangalore S; Reed M; Meier P; Zoccai G; Gaita F
Am J Cardiol; 2015 May; 115(9):1185-93. PubMed ID: 25799015
[TBL] [Abstract][Full Text] [Related]
14. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
15. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
[TBL] [Abstract][Full Text] [Related]
16. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
Ganetsky VS; Hadley DE; Thomas TF
Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
[TBL] [Abstract][Full Text] [Related]
17. Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.
Bhatia K; Ladd LM; Carr KH; Di Napoli M; Saver JL; McCullough LD; Hosseini Farahabadi M; Alsbrook DL; Hinduja A; Ortiz Garcia JG; Sabbagh SY; Jafarli A; Divani AA
Curr Neurol Neurosci Rep; 2023 May; 23(5):235-262. PubMed ID: 37037980
[TBL] [Abstract][Full Text] [Related]
18. Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence.
Davis KA; Miyares MA; Dietrich E
Am J Health Syst Pharm; 2015 Oct; 72(19):1623-9. PubMed ID: 26386103
[TBL] [Abstract][Full Text] [Related]
19. Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.
De Caterina R; Husted S; Wallentin L; Andreotti F; Arnesen H; Bachmann F; Baigent C; Collet JP; Halvorsen S; Huber K; Jespersen J; Kristensen SD; Lip GY; Morais J; Rasmussen LH; Ricci F; Sibbing D; Siegbahn A; Storey RF; Ten Berg J; Verheugt FW; Weitz JI
Thromb Haemost; 2016 Apr; 115(4):685-711. PubMed ID: 26952877
[TBL] [Abstract][Full Text] [Related]
20. [Anticoagulant therapy in secondary prevention of coronary events].
Bultas J
Vnitr Lek; 2014 Dec; 60(12):1023-32. PubMed ID: 25692828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
